Volasertib trihydrochloride

Synonyms: 伏拉塞替三盐酸盐; BI 6727 trihydrochloride
Volasertib (BI 6727) trihydrochloride 是一种具有口服活性的、高效的、ATP 竞争性 Polo 样激酶 1 (PLK1) 抑制剂(IC50 为 0.87 nM),同时抑制 PLK2 和 PLK3(IC50 分别为 5 和 56 nM),可诱导有丝分裂停滞和细胞凋亡,作为一种二氢蝶呤酮衍生物,在多种癌症模型中显示出显着的抗肿瘤活性。
产品编号: MS-A61860 纯度: 99.12% CAS No.: 946161-17-7 分子式: C34H53Cl3N8O3 分子量: 728.20
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Volasertib (BI 6727) trihydrochloride 是一种具有口服活性的、高效的、ATP 竞争性 Polo 样激酶 1 (PLK1) 抑制剂(IC50 为 0.87 nM),同时抑制 PLK2 和 PLK3(IC50 分别为 5 和 56 nM),可诱导有丝分裂停滞和细胞凋亡,作为一种二氢蝶呤酮衍生物,在多种癌症模型中显示出显着的抗肿瘤活性。

生物实验数据

生物活性 Volasertib (BI 6727) trihydrochloride is an orally active, highly potent, ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM that also inhibits PLK2 and PLK3 with IC50 values of 5 and 56 nM, respectively, induces mitotic arrest and apoptosis, and, as a dihydropteridinone derivative, exhibits significant antitumor activity in multiple cancer models.
IC50 & Target PLK3:56 nM, PLK2:5 nM, PLK1:0.87 nM
体外研究
(In Vitro)

Volasertib trihydrochloride (BI 6727 trihydrochloride; 0.01-10000 nM; 72 hours) has EC50 values of 11 to 37 nmol/L in multiple cell lines.
Volasertib trihydrochloride (10-1000 nM; 24 hours) results accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase.
Volasertib trihydrochloride (100 nM; 24-72 hours) induces cell apoptosis at 48 hours.

Cell Proliferation Assay

Cell Line: Multiple cell lines
Concentration: 0.01-10000 nM
Incubation Time: 72 hours
Result: Inhibited proliferation of multiple cell lines derived from various cancer tissues, including carcinomas of the colon (HCT 116, EC50=23 nmol/L) and lung (NCI-H460, EC50=21 nmol/L), melanoma (BRO, EC50=11 nmol/L), and hematopoietic cancers (GRANTA-519, EC50=15 nmol/L; HL-60, EC50=32 nmol/L; THP-1, E50=36 nmol/L and Raji, EC50=37 nmol/L) with EC50 values of 11 to 37 nmol/L.

Apoptosis Analysis

Cell Line: NCI-H460 cells
Concentration: 100 nM
Incubation Time: 24, 48, 72 hours
Result: G2-M arrest at 24 hours was followed by induction of apoptosis at 48 hours.

Cell Cycle Analysis

Cell Line: NCI-H460 cells
Concentration: 10, 30, 100, 300, 1000 nM
Incubation Time: 24 hours
Result: Resulted in accumulation of cells with 4N DNA content, indicative of a cell cycle block in G2-M phase.
体内研究
(In Vivo)

Volasertib trihydrochloride (BI 6727 trihydrochloride; A total weekly dose of 50 mg/kg; Oral; once a week, twice a week, or daily; for 40 days) shows comparable efficacy in human colon carcinoma xenograft models.
Volasertib trihydrochloride (15, 20, or 25 mg/kg/day; i.v.; 2 consecutive days per week; for 40 days) leads to significant tumor growth delay and even tumor regression in human colon carcinoma xenograft models.
Volasertib trihydrochloride (70 mg/kg given once weekly or 10 mg/kg daily; oral) significantly delays tumor growth in a non-small cell lung carcinoma xenograft model derived from NCI-H460 cells.
Volasertib (a single dose of 40 mg/kg; iv) causes a significant (13-fold) increase in mitotic cells in HCT 116 tumor-bearing nude mice.
Volasertib has high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h).

Animal Model: Female BomTac:NMRI-Foxn1nu mice (Taconic) were grafted s.c. with HCT 116 human colon carcinoma cells (ATCC CCL-247)
Dosage: A total weekly dose of 50 mg/kg
Administration: Oral; once a week, twice a week, or daily; for 40 days
Result: Showed comparable efficacy and were well tolerated.
Animal Model: Female BomTac:NMRI-Foxn1nu mice and male Wistar rats of the strain Crl:WI
Dosage: 35 mg/kg (mice) or 10 mg/kg (rat) (Pharmacokinetic Analysis)
Administration: IV 5-minute infusion; a single dose 5-minute infusion
Result: Had high volume of distribution and a long terminal half-life in mice (Vss=7.6 L/kg, t1/2=46 h) and rats (Vss=22 L/kg, t1/2=54 h).
性状 固体
颜色 Off-white to light yellow

化学信息

分子量 728.20
分子式 C34H53Cl3N8O3
CAS No. 946161-17-7
别名 伏拉塞替三盐酸盐; BI 6727 trihydrochloride

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (137.32 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : ≥ 100 mg/mL (137.32 mM)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM1.3732 mL6.8662 mL13.7325 mL34.3312 mL
5 mM0.2746 mL1.3732 mL2.7465 mL6.8662 mL
10 mM0.1373 mL0.6866 mL1.3732 mL3.4331 mL
15 mM0.0915 mL0.4577 mL0.9155 mL2.2887 mL
20 mM0.0687 mL0.3433 mL0.6866 mL1.7166 mL
25 mM0.0549 mL0.2746 mL0.5493 mL1.3732 mL
30 mM0.0458 mL0.2289 mL0.4577 mL1.1444 mL
40 mM0.0343 mL0.1717 mL0.3433 mL0.8583 mL
50 mM0.0275 mL0.1373 mL0.2746 mL0.6866 mL
60 mM0.0229 mL0.1144 mL0.2289 mL0.5722 mL
80 mM0.0172 mL0.0858 mL0.1717 mL0.4291 mL
100 mM0.0137 mL0.0687 mL0.1373 mL0.3433 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础